marketscreener.comOCT 161 min read

Goldman Sachs raises price target for Loomis to SEK 640 (610), reiterates neutral - BN

Goldman Sachs increased its price target for Loomis to SEK 640 from SEK 610, maintaining a neutral rating. The company's stock has risen 4.05% year-to-date and 47.93% over the past year, trading at 577.50 SEK. JP Morgan also holds a significant stake in Loomis.

Original reporting

marketscreener.com

Published Oct 16, 2026, 4:34 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 16, 2026, 5:09 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

MARKET

Neutral

AI market analysis

Mentioned

$LOIMF

Relevance

5/10

AlphAI data visualization · based on marketscreener.com

Decision brief

The 30-second read

Low

Why it matters

The upgrade signals modest optimism but retains a neutral rating, implying limited immediate trading impetus.

Market read

A modest analyst upgrade with neutral rating; likely limited impact on price.

What to watch

Potential macro‑economic headwinds in Europe could dampen the expected upside.

Relevance 5/10Novelty 5/10Timing: pre‑market

Background

Goldman Sachs issued a new price target for Loomis AB, a Swedish security services firm, raising it to SEK 640 from a prior level.

Market effects

Sector

May slightly lift the security services sector in Sweden.

Regional

Limited to Nordic markets; no broad regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The neutral stance suggests caution; the target raise may be premature.

Key entities

company
Loomis AB
Swedish security services provider listed on Nasdaq Stockholm.
analyst
Goldman Sachs
Investment bank providing the price target upgrade.

Read at source ← All news

OCT 16

$JPMMed

JP Morgan crosses 5% in Loomis

JP Morgan Asset Management Holdings acquired a 5% stake in Loomis AB, a Sweden-based cash management company, on October 13, owning 3.35m shares. Loomis provides cash handling services to various sectors globally. The company operates in multiple countries and has over 200 cash processing centers.

marketscreener.com1 min

OCT 5

MedAI 9/10

Loomis completes the acquisition of Hermes Transportes Blindados

Loomis has finalized its acquisition of 99.80% of Hermes Transportes Blindados for approximately $297 million. Hermes, a Peru-based security logistics firm, will be integrated into Loomis' Europe and Latin America segment. The deal strengthens Loomis' presence in Latin America and was financed through a bond issuance.

prnewswire.com2 min

AUG 5

$CLow

Citigroup Settles $70 Million Trade-Loss Suit With Loomis Sayles

Citigroup Inc. settled a trade-loss lawsuit brought by Loomis, Sayles & Co. over alleged execution of orders that caused more than $70 million in losses, according to court filings. The parties told a federal judge they will drop the case without refiling and did not disclose settlement terms. The suit involved Citi as broker for trades in Shopify and Colgate-Palmolive.

claimsjournal.com3 min

JUL 24

Med

Loomis Interim Report January - June 2026

Loomis AB reported Q2 (Apr-Jun 2026) revenue of SEK 7,891 million, up 9.1% currency-adjusted, with EBITA of SEK 1,102 million and EBITA margin rising to 14.0%. Profit for the period was SEK 608 million, EPS SEK 9.09 basic. Operating cash flow was SEK 683 million. Loomis announced acquisitions in Argentina and Peru.

prnewswire.com6 min

OCT 25

$XNCRHighAI 8/10

Xencor reports phase 1 data for cancer drug XmAb819

Xencor Inc. (XNCR) reported Phase 1 trial results for XmAb819, a cancer drug, showing a 45.5% response rate at the 400 mcg/kg dose. The company plans to discuss accelerated approval with the FDA and initiate a global trial comparing XmAb819 with tivozanib. Adverse events were reported in 72.1% of patients, with liver enzyme elevations being the most common.

investing.com2 min